FDA Clears 15-Minute Blood Diagnostic for Early-Stage Alzheimer's Biomarkers
The Big Picture • 3 Key Facts
Enables millions of American families to detect neurodegenerative pathology up to a decade before clinical memory loss occurs—the precise window when modern disease-modifying monoclonal antibody therapies produce their highest clinical efficacy.
Neurological Consensus
Leading dementia specialists describe the test as the most consequential preventative diagnostic leap in decades, democratizing routine screening directly within suburban community doctor offices.
Counseling Protocol Demands
Primary care physician associations caution that widespread rapid testing must be accompanied by comprehensive genetic and emotional counseling protocols so asymptomatic patients are not left without clinical guidance upon receiving positive biomarker results.